Theravance Biopharma, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Theravance Biopharma, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.14M.
- Theravance Biopharma, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $241.00K.
- Theravance Biopharma, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $488.00K.
- Theravance Biopharma, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $278.00K.
- Theravance Biopharma, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $766.00K.
- Theravance Biopharma, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $5.00K, a 99.63% decline from fiscal 2020.
- Theravance Biopharma, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $1.36M, a 56.68% decline from fiscal 2019.
- Theravance Biopharma, Inc. stock issued during period, value, stock options exercised for fiscal 2019 was $3.14M, a 125.56% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.14M 10-Q · filed 2026-08-11 | $2.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $241.00K 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $488.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $766.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $278.00K 10-Q · filed 2025-11-12 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $5.00K 10-K · filed 2023-03-01 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $406.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $2.00K 10-Q · filed 2022-08-08 | $430.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $3.00K 10-Q · filed 2022-05-06 | $1.16M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $1.36M 10-K · filed 2023-03-01 |
| 2020-09-30 | $24.00K 10-Q · filed 2021-11-08 | $1.13M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $733.00K 10-Q · filed 2021-08-05 | $1.53M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $203.00K 10-Q · filed 2021-05-06 | $3.09M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $169.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.14M 10-K · filed 2022-02-28 |
| 2019-09-30 | $428.00K 10-Q · filed 2020-11-09 | $3.06M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $2.29M 10-Q · filed 2020-08-10 | $3.86M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $254.00K 10-Q · filed 2020-05-08 | $1.61M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $1.39M 10-K · filed 2021-02-26 |
| 2018-09-30 | $1.23M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $46.00K 10-Q · filed 2019-08-05 | |
| 2018-03-31 | $35.00K 10-Q · filed 2019-05-10 | |
| 2017-12-31 | $6.24M 10-K · filed 2020-02-27 | |
| 2016-12-31 | $4.38M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |